Abrinica, Clyde .

HRN: 27-22-75  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/02/2025
CEFTRIAXONE 1G (VIAL)
06/02/2025
06/09/2025
IV
660mg
Q24
PCAP D
Waiting Final Action 
06/04/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/04/2025
06/10/2025
IV
40mg
Q12
PCAP D
Waiting Final Action 
06/05/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/05/2025
06/12/2025
IV
350mg
Q6h
PCAP D
Remove - Pending Acceptance
06/12/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/12/2025
06/15/2025
IV
350mg
Q6h
PCAP
Remove - Pending Acceptance
06/24/2025
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
06/24/2025
07/01/2025
PO
2ml
Q 12
PCAP-D
Waiting Final Action 
06/24/2025
MUPIROCIN 2%, 15G (TUBE)
06/24/2025
07/01/2025
TOPICAL
As Needed
Q 12
T/C Dermatitis
Waiting Final Action 
06/24/2025
SODIUM FUSIDATE 20MG/G, 15G OINTMENT
06/24/2025
07/01/2025
TOPICAL
As Needed
Q 12
T/C Dermatitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: